On 12 November, a gene-editing company reported that a treatment it built for a rare inherited swelling disorder is still holding after four years, placing a long-sought idea within reach of regulators. The therapy, lonvo-z, works by switching off a liver gene inside the body itself rather than by altering a patient's cells outside it and returning them. Its fate now rests with the US Food and Drug Administration, which is expected to rule by 10 March. If approved, it would mark a turning point: the moment genetic medicine stops requiring a laboratory detour and begins working where the diseas
Intellia's In Vivo CRISPR Therapy Nears First FDA Approval as Four-Year Data Holds
Four years on, the edit made inside the body is still holding
Mark
Why does a four-year result matter so much here?
Mimi
Gene editing is meant to be a one-time fix. If the effect faded after a year, the premise would fail. Four years of effect suggests the edit is holding.
Luke
Worth noting that figure comes from Intellia itself, released by the developer. It isn't an independent analysis.
Mark
And what's different from Casgevy?
Mimi
Casgevy takes cells out, edits them, and puts them back, with chemotherapy first. Lonvo-z is a one-day infusion into the blood, and the liver does the rest.
Mark
So it's simply better?
Luke
Not simply. Inside the body you can't screen for stray edits in the genome or other organs, and immune reactions are possible. Those are open concerns.
Mimi
Which is why long-term follow-up matters as much as the approval itself.
Mark
What does it mean for patients?
Mimi
Bernstein, who's an investigator on a trial, describes escaping a lifetime of medications for preventing and treating attacks.
Luke
He's also involved in the trial, so I'd read that as a clinician's reassurance, not a verdict. The FDA decision by 10 March is the real test.
O Pulso
- A single infusion of fatty particles carries gene-editing instructions straight into the liver, where the faulty protein is made.
- Patients with hereditary angioedema live under the threat of sudden, dangerous swelling, and lonvo-z aims to end the daily juggling of preventive drugs.
- The FDA review is underway, with a decision expected by 10 March that will decide whether the first in-body CRISPR medicine reaches patients.
- Four years of durable results are encouraging, but they come from the developer, leaving independent confirmation still to come.
- Open questions about unintended edits elsewhere in the genome and harmful immune reactions will shape how far this approach can travel.
On 12 November, a gene-editing company reported that a treatment it built for a rare inherited swelling disorder is still holding after four years, placing a long-sought idea within reach of regulators. The therapy, lonvo-z, works by switching off a liver gene inside the body itself rather than by altering a patient's cells outside it and returning them. Its fate now rests with the US Food and Drug Administration, which is expected to rule by 10 March. If approved, it would mark a turning point: the moment genetic medicine stops requiring a laboratory detour and begins working where the disease lives.
On 12 November, Intellia Therapeutics chief executive John Leonard told investors that the company's gene-editing treatment is still working four years after patients received it. The therapy, lonvoguran ziclumeran or lonvo-z, is now before the US Food and Drug Administration, which is expected to decide by 10 March.
Lonvo-z treats one form of hereditary angioedema, a genetic disorder that causes painful and sometimes dangerous swelling in the throat and elsewhere in the body. It uses CRISPR-Cas9 to disable the gene for prekallikrein, a liver protein that drives blood-vessel leakage. The particles carrying the editing instructions are infused into the bloodstream and taken up by the liver, and the procedure takes one day. If approved, it would be the first CRISPR medicine delivered directly inside the body.
The contrast with Casgevy, the only CRISPR therapy approved so far, is stark. That treatment removes a patient's blood stem cells, edits them outside the body, and infuses them back after harsh chemotherapy, with each dose made individually. In vivo editing sidesteps those burdens, but it cannot screen out unwanted changes before they take hold, and recipients could mount harmful immune responses.
For patients, the promise is a life freed from constant medication. Specialist Jonathan Bernstein, an investigator on a lonvo-z trial, called the four-year data very reassuring. Because the results come from Intellia itself rather than an independent review, the 10 March decision and long-term follow-up on safety will determine how the story ends.
On 12 November, Intellia Therapeutics chief executive John Leonard told investors that a gene-editing treatment his company built is still working four years after patients received it. The therapy, lonvoguran ziclumeran, or lonvo-z, is now under review at the US Food and Drug Administration, which is expected to decide by 10 March.
Lonvo-z targets one form of hereditary angioedema, a genetic disorder that causes episodes of painful and potentially dangerous swelling in the throat and other parts of the body. The therapy uses the CRISPR-Cas9 system to disable the gene that produces prekallikrein, a protein made in the liver that promotes blood-vessel leakage.
What sets it apart is where the editing happens. The treatment consists of fatty particles that encase mRNA encoding the CRISPR-Cas9 components. The particles are infused into the bloodstream and taken up by the liver, the organ where prekallikrein is made. The procedure takes one day. If the FDA approves it, Leonard said, lonvo-z would be the world's first CRISPR medicine delivered directly inside the body, known as in vivo.
The only CRISPR therapy now approved by the FDA is Casgevy, which treats two genetic blood disorders, sickle cell anemia and beta-thalassemia. It works the other way around. Physicians remove blood stem cells from the patient and send them off for gene editing, and the edited cells are then infused back. Each dose has to be made anew for the individual, which adds time, cost, and complexity. Patients must also undergo harsh chemotherapy to make room for the edited cells.
In vivo editing aims to sidestep those burdens. It brings its own safety questions, though. Because the edit happens inside the body, there is no chance to screen out cells carrying unwanted changes elsewhere in the genome or in other organs. Recipients might also mount harmful immune responses to the treatment.
For patients, the appeal is plain. Jonathan Bernstein, a hereditary angioedema specialist at the University of Cincinnati in Ohio and an investigator on a lonvo-z trial, says the approach could relieve people of a lifetime of juggling medications to prevent and treat swelling attacks. Of the four-year data, he says it is very reassuring, and that it is what you are supposed to see.
Intellia, headquartered in Cambridge, Massachusetts, has made the durability findings public through its own release, so they come from the developer rather than an independent review. The 10 March decision is the next marker, and after it, continued follow-up on off-target edits and immune reactions will show how the safety questions resolve.
Citações Notáveis
Of the four-year data: 'It's very reassuring. That's what you're supposed to see.'— Jonathan Bernstein, University of Cincinnati, lonvo-z trial investigator
Quer a matéria completa?
Leia o original em Nature ↗